NICE recommends Keytruda® (pembrolizumab) for triple-negative breast cancer

Nov 8, 2022

NICE published final draft guidance recommending Keytruda® (pembrolizumab) for the treatment of triple-negative breast cancer.  NICE expects to publish its final guidance on pembrolizumab for treating early or locally advanced triple-negative breast cancer next month (December 2022).

Print Page Mail Article